Global recruitment of Principal Investigator

1. Job Summary

As the innovation and drug discovery hub of SINOVAC, the United Research Institute of SINOVAC (URIS) is committed to "uniting the power of global science and promoting global health". Established in 2023, URIS focuses on unmet medical needs, integrating cutting-edge research and significant findings to develop first-in-class innovation in vaccines, antibodies, and cell gene therapy, accelerating the market launch of high-quality products.

URIS is recruiting principal investigators (PI) to manage research teams focused on drug development for infectious diseases, metabolic diseases, oncology, neurological diseases, and autoimmune diseases. As the “CEO” of the designated research direction, the PI is fully responsible for overall planning and project implementation. Through cross-functional cooperation, both internal and external to the team, the PI will solve cutting-edge problems, focusing on unmet needs regarding diseases, and carry out innovative drug R&D.

2. Roles and Responsibilities

1. Develop and implement R&D strategies in the field of diseases.
2. Conduct research on early drug development projects, responsible for project planning and implementation to specific goals.
3. Provide leadership and expert scientific guidance to teams; continually optimize best practice; deliver results that meet quality and productivity objectives.
4. Responsible for managing and progressing collaborative transformation research projects, independently developing research topics/project capabilities; combining  research with goal developments and implement them.
5. Advise senior management on project strategies and scientific de-risking. Through internal or external collaboration with cross-functional teams, solving cutting-edge problems, focusing on unmet medical needs regarding diseases, and carrying out innovative drug R&D..
6. Facilitate and mentor group members in effective communication and teamwork within the group, project teams, and intra- and inter-departmental functions.

3. Qualification and Requirements

1. Ph.D in biology/medicine/virology/immunology/clinical practice or any relevant field.
2. More than 10 years of relevant work experience in research, drug development/review/R&D management/clinical trials/clinical treatment; have led crucial scientific research projects, or worked as an associate professor or above in well-known universities.
3. Sound knowledge of biopharmaceutical research and clinical practice related to infectious diseases/chronic diseases/tumors/antibody drugs/CGTs.
4. Experience in independently developing research projects, and experience in transformation to further research goals. Priority will be given to those with successful product or drug development experience (completing clinical trials or achieving market launch).
5. Experience in managing an internal team and external stakeholders.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a Chinese biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines and antibodies. SINOVAC also produces other preventive and therapeutic products that protect against human infectious diseases.

SINOVAC is dedicated to addressing major challenges in disease prevention and treatment through cutting-edge technology. We focus on unmet medical needs regarding infectious disease and other significant therapeutic areas. All our work integrates cutting-edge research and major findings from across the world, concentrating strengths to develop first-in-class biopharmaceuticals such as vaccines, antibodies, and fusion proteins, ensuring high-quality products reach the market swiftly. Our high R&D standards are backed by innovation-driven platforms such as the United Research Institute of SINOVAC (URIS) for drug discovery and our product-oriented CMC platform. We also run clinical demand support platforms such as our Analysis Center and Animal Center for Drug Evaluation. Our world-class facilities mean we have a mature system for developing preventive and therapeutic products, with multiple types of technologies including our own core technologies. Our multidisciplinary research team, covering fields such as pharmacy, biology, medicine, and chemistry, are at the forefront of global research and innovation.

Going forward, SINOVAC will promote both the research and industrialization of biopharmaceuticals. While continuing to develop its vaccine industry, we will also expand our markets in therapeutic monoclonal antibodies, gene therapy, and cell therapy. Through independent R&D, collaboration, and external investment, we will accelerate the industrialization of high-quality biopharmaceuticals to fulfil global disease prevention and control, improving global health and well-being.

Since being founded in 2001, our mission has been to “supply vaccines to eliminate human diseases”. SINOVAC has developed a comprehensive portfolio including vaccines against common infectious diseases like hepatitis virus, seasonal influenza, pneumococcal disease, poliomyelitis, varicella, and mumps, as well as emerging ones, such as COVID-19, enterovirus71 (EV71) related Hand-Foot-Mouth disease (HFMD), H5N1 influenza (avian flu), H1N1 influenza (swine flu) and SARS.

Thanks to its comprehensive quality management, SINOVAC has four vaccines approved by the World Health Organization (WHO). Its hepatitis A vaccine Healive®, Sabin-strain inactivated poliomyelitis vaccine (sIPV), and varicella vaccine were granted WHO prequalification ("PQ"); and its COVID-19 vaccine CoronaVac® was validated by the WHO under the Emergency Use Listing ("EUL") Procedure.